There are few cost evaluation studies of orthodontic treatment. The aim of this study was to determine the costs of correcting posterior crossbites with Quad Helix (QH) or expansion plates (EPs) and to relate the costs to the effects. To determine which alternative has the lower cost, a cost-minimization analysis was undertaken, based on that the outcome of the treatment alternatives is identical. The study comprised 40 subjects in the mixed dentition, who had undergone treatment for unilateral posterior crossbite: 20 with QH and 20 with EPs. Duration of treatment, number of appointments, broken appointments, and cancellations were registered. Direct costs (for the premises, staff salaries, material and laboratory costs) and indirect costs (loss of income due to parent's assumed absence from work) were calculated and evaluated for successful treatment alone, for successful and unsuccessful treatment and re-treatment when required. The QH had significantly lower direct and indirect costs, with fewer failures requiring re-treatment. Even the costs for successful cases only were significantly lower in the QH than in the EP group. The results clearly show that in terms of cost-minimization, QH is the preferred method for correcting posterior crossbite in the mixed dentition.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/ejo/cjr047 | DOI Listing |
Ther Adv Med Oncol
January 2025
Department of Oncology, Zhuzhou Second Hospital, Zhuzhou, Hunan 412000, China.
Background: Both the antibody-drug conjugate (ADC) enfortumab vedotin (EV) and programmed death-1 inhibitor pembrolizumab have been shown to provide survival benefits in patients previously treated with locally advanced or metastatic urothelial carcinoma (la/mUC). Cost-effectiveness is necessary to consider whether the increased efficacy of the two therapies will lead to higher prices for first-line treatment of previously untreated la/mUC.
Objectives: To guide the choice of EV plus pembrolizumab or chemotherapy for patients with previously untreated la/mUC.
Neurooncol Pract
February 2025
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
The isocitrate dehydrogenase (IDH) inhibitor, vorasidenib, may offer a promising new treatment option for patients with IDH-mutant gliomas. However, the indefinite nature of this targeted therapy raises significant financial concerns. High costs of targeted cancer therapies, often exceeding $150 000 annually, contribute to financial toxicity, characterized by medical debt, income loss, and psychological stress, and place stress on health systems.
View Article and Find Full Text PDFFront Public Health
December 2024
Department of Epidemiology and Biostatistics, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Background: The increase in the dual burden of HIV and cardiovascular diseases (CVD), calls for the provision of integrated HIV/CVD care. This study aimed to explore barriers and facilitators to the integration of HIV/CVD care within HIV care and treatment clinics (CTCs) in urban, Tanzania.
Methods: Between March and April 2023, we conducted 12 key informant interviews with healthcare providers at six HIV CTCs in urban, Tanzania.
Front Public Health
December 2024
Department of Management Sciences, City University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Background: Homecare, a cornerstone of public health, is essential for health systems to achieve the Sustainable Development Goal (SDG) of universal health coverage while maintaining its own sustainability. Notwithstanding homecare's system-level significance, there is a lack of economic evaluations of homecare services in terms of their system-wide cost-savings. Specifically, decisions informed by a joint medical-social budgetary perspective can maximize the allocative efficiency of assigning a diverse service mix to address the complex needs of the older adult population.
View Article and Find Full Text PDFLangenbecks Arch Surg
January 2025
Department of Surgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Charité Mitte and Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany.
Purpose: Despite ongoing discussions concerning clinical equivalence of laparoscopic total gastrectomy (LTG) compared to open total gastrectomy (OTG) in gastric cancer (GC) surgery, complementary evidence regarding financial implications is sparse. The aim of this study was to compare hospital associated expenses and perioperative outcomes between both approaches.
Methods: Clinicopathological and financial data from 80 consecutive GC patients undergoing LTG or OTG between 2015 and 2022 were investigated.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!